AI Article Synopsis
- * Two genetic tools were employed to analyze the effects of LDL-C-lowering and triglyceride-lowering drugs, with various statistical analyses revealing the impacts of these drugs.
- * Results indicated that PCSK9 inhibitors could potentially reduce the risk of aortic valve stenosis, while no significant impact was found for triglyceride-lowering drugs.
Article Abstract
Background: Lipid metabolism plays an important role in the pathogenesis and development of calcific aortic valve stenosis. Our aim was to evaluate the causal effect of lipid-lowering drugs, such as low-density lipoprotein cholesterol (LDL-C) lowering and triglyceride lowering drugs, on the outcome of aortic valve stenosis using a two-sample Mendelian randomization (MR) study.
Methods: We used two genetic tools to represent the exposure of lipid-lowering drugs, including expression quantitative trait loci for the expression of drug target genes, and genetic variants within or near drug target genes that are associated with LDL-C and triglyceride concentrations from Genome-Wide Association Studies (GWAS). Effect estimates were calculated using summary-data-based MR (SMR) and inverse-variance-weighted MR (IVW-MR) analysis.
Results: Based on the results of SMR and IVW-MR analysis, LDL-C-lowering PCSK9 inhibitors have potential in reducing the risk of aortic valve stenosis (for SMR, OR: 1.044; 95%CI: 1.002-1.404; = 0.047; for IVW-MR, OR: 1.647, 95%CI: 1.316-2.062, < 0.001). However, no significant association was observed between triglyceride target gene expression, as well as triglyceride-lowering drugs, and aortic valve stenosis.
Conclusion: This two-sample drug-targeted MR study suggests a potential causal relationship between PCSK9 inhibitors and the reduction of calcific aortic valve stenosis risk.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11269895 | PMC |
| http://dx.doi.org/10.1016/j.heliyon.2024.e34089 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of aortic valve calcification on transcatheter aortic valve replacement for low-flow, low-gradient aortic stenosis.
Cardiovasc Revasc Med
January 2025
Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address:
Background: Patients with low-flow, low-gradient (LFLG) aortic stenosis (AS) have precarious hemodynamics and are a fragile population for intervention. Quantification of aortic valve calcification (AVC) severity is a critical component of the evaluation for transcatheter aortic valve replacement (TAVR); this study aims to further clarify its utility for risk stratification in LFLG AS.
Methods: This retrospective study evaluated 467 patients with LFLG AS undergoing TAVR at a large quaternary-care hospital from January 2019 to December 2021.
Sex-Specific Anatomic Differences in Patients Undergoing Transcatheter Aortic Valve Implantation: Insights from the ST-TAVI Registry.
Hellenic J Cardiol
January 2025
Department of Cardiology, University Hospital of Split, 21000 Split, Croatia. Electronic address:
Background: Anatomic considerations of transcatheter aortic valve implantation (TAVI) have an important role for the procedure planning, but sex-specific data are lacking.
Methods: All eligible cases undergoing evaluation for TAVI procedure in the period from November 2019 to July 2023 at the University Hospital of Split were included. Cardiac computed tomography was analysed to derive the measures of left ventricular outflow tract (LVOT), aortic root, ascending aorta, and ilio-femoral arteries.
The prevalence of aortic stenosis in Māori undergoing clinically indicated echocardiography compared to New Zealand Europeans.
N Z Med J
January 2025
Department of Medicine, HeartOtago, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; Department of Cardiology, Dunedin Hospital, Southern District Health Board, Dunedin, New Zealand.
Aim: There are limited data on the prevalence of calcific aortic valve disease (CAVD) in Māori and known inequities in outcomes after aortic valve intervention. Our study aimed to investigate the prevalence of CAVD in Māori.
Methods: Data from initial clinically indicated echocardiograms performed between 2010 to 2018 in patients aged ≥18 years were linked to nationally collected outcome data.
Cardiovascular Disease-Specific Responses to Autonomic Denervation.
JACC Clin Electrophysiol
January 2025
Department of Cardiovascular Surgery, General Hospital of Northern Theater Command, Shenyang, Liaoning, China. Electronic address:
Background: Calcium-mediated autonomic denervation has been shown to suppress postoperative atrial fibrillation (POAF) after coronary artery bypass grafting.
Objectives: This study sought to evaluate whether similar autonomic denervation can prevent POAF after mitral or aortic valve surgeries.
Methods: This research consisted of 2 single-center, randomized, double-blind, sham-controlled trials: CAP-AF2 (Calcium Autonomic Denervation Prevents Postoperative Atrial Fibrillation in Patients Undergoing Isolated Mitral Valve Surgery for Mitral Regurgitation) for mitral valve (MV) surgery and CAP-AF3 (Calcium Autonomic Denervation Prevents Postoperative Atrial Fibrillation in Patients Undergoing Isolated Aortic Valve Surgery) for aortic valve surgery.
Plus Anchor Valve Replacement for Treatment of Severe Aortic Regurgitation With an Extremely Large Annulus.
JACC Cardiovasc Interv
December 2024
Center for Cardiovascular Diseases, Meizhou People's Hospital, Meizhou, China; Guangdong Provincial Engineering and Technological Research Center for Molecular Diagnostics of Cardiovascular Diseases, Meizhou, China. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!